CNS Pharma (CNSP) Total Debt to Capital

CNS Pharmaceuticals, Inc. - graphic logo of issuer CNSP

This price chart illustrating trading dynamics shows the separate_debt_total_eq metric at 0.00. The CNS Pharmaceuticals (CNSP) business relies on inelastic demand in oncology, making it resilient to economic crises. High authority within the medical community and trust in the drug Berubicin strengthen the brand's position. The company is distinguished by large-scale investments in the development of blood-brain barrier penetrating agents to combat glioblastoma.

cnspharma.com (CNSP): Debt to Equity Ratio from 07/04/2022 to 10/31/2026

Metric breakdowns and analytics for CNS Pharmaceuticals Corp (CNSP)

- share price and consensus valuation forecast:
Stock Price CNS Pharmaceuticals, Inc.|CNSP - Consensus Target
- market capitalization details:
Market Capitalization CNS Pharmaceuticals|CNSP - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share CNS Pharmaceuticals|CNSP - Accounting Capitalization|Market Capitalization to Book Value Ratio cnspharma.com|CNSP - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital CNS Pharmaceuticals|CNSP - Long-Term Liabilities to Capital|Short-Term Debt to Equity CNS Pharmaceuticals|CNSP - Aggregate Debt Obligations|Debt to Book Value CNS Pharmaceuticals|CNSP - Company Long-Term Loans and Borrowings|Company Short-Term Debts CNS Pharmaceuticals|Quick Liquidity cnspharma.com
- net income and valuation ratios data:
CNSP - Final Profit
Fundamental company valuation:CNS Pharmaceuticals, Inc.
Finished products of CNS Pharmaceuticals

Liquidity is critical for the biotech company CNS Pharmaceuticals (CNSP), which faces high pre-commercial risks and is awaiting data on Berubicin. This ratio compares total liabilities to net assets, determining the business's degree of dependence on borrowed capital and its overall solvency. Analyzing the company's financial leverage history allows for an assessment of how effectively the balance sheet structure protects the investor during periods of uncertainty prior to the drug's commercialization.

Competitor analysis for CNS Pharmaceuticals

SHPH (Shuttle Pharmaceuticals Holdings) - Total Debt to Capital